| Novel therapeutics based on inhibiting the interaction of glycogen phosphorylase and GL-subunit of glycogen-associated protein phosphatase 1: WO2009127723. | |
| | |
MedLine Citation:
|
PMID: 20367521 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Diabetes mellitus is a major challenge for healthcare systems worldwide because it is strongly associated with several major health risk factors. Currently marketed drugs are insufficient to achieve long-term control of blood glucose levels and induce considerable side effects. The development of more effective drugs for metabolic diseases is still of urgent interest. Recently, inhibiting the interaction of hepatic glycogen-targeting subunit (G(L)) of protein phosphatase 1 and glycogen phosphorylase a (GPa) is emerging as a novel mechanism to combat diabetic hyperglycemia by dephosphorylation and activation of glycogen synthase, converting high blood glucose to liver glycogen. Patent WO2009127723 describes a variety of arylsulfonylaminomethylphosphonic acids as small molecule inhibitors of G(L)-GPa interaction and their potential use as pharmaceutical compositions to treat type 1 and type 2 diabetes mellitus. Although lacking detailed in vivo biological data, WO2009127723 represents the first evidence for the novel rationale in antidiabetic pursuit, meriting the attention of the antidiabetic community. |
| | |
Authors:
|
Lei Zhang; Hong Liu |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on therapeutic patents Volume: 20 ISSN: 1744-7674 ISO Abbreviation: Expert Opin Ther Pat Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-17 Completed Date: 2010-09-22 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9516419 Medline TA: Expert Opin Ther Pat Country: England |
Other Details:
|
Languages: eng Pagination: 969-73 Citation Subset: IM |
Affiliation:
|
Drug Discovery and Design Centre, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus, Type 1
/
drug therapy,
enzymology Diabetes Mellitus, Type 2 / drug therapy, enzymology Drug Delivery Systems Drug Design Glycogen Phosphorylase / metabolism* Humans Hypoglycemic Agents / pharmacology* Patents as Topic Protein Phosphatase 1 / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; EC 2.4.1.-/Glycogen Phosphorylase; EC 3.1.3.16/Protein Phosphatase 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Preemptive dexamethasone and etoricoxib for pain and discomfort prevention after periodontal surgery...
Next Document: Medical abortion in lactating women - low levels of mifepristone in breast milk.